Louise Chick
reflexology & reiki practitioner

Phone: 0404 917 510
[email protected]

Bondi Junction

Happiness Reflexology in Randwick

Buy Bromocriptine (Parlodel) online

How and where to order Parlodel (Bromocriptine Mesylate) 1.25 mg and 2.5 mg tablets online on the Happiness Reflexology website:

Shop:MEDS FOR SALE - 5% discount coupon 5OFF
Prices:from $1.66 per pill
Forms:Bromocriptine Mesylate 1.25 mg, 2.5 mg tablets
Quantity:10-300 pills
Type:Bromocriptine brand, Sicriptin brand, Parlodel generic
Payment:Visa, Mastercard, AmEx, Cryptocurrency
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Parlodel (Bromocriptine Mesylate) is an ergoline derivative and dopamine agonist indicated for:

  • Hyperprolactinemia-associated dysfunctions, including amenorrhea with or without galactorrhea, infertility, hypogonadism, prolactin-secreting adenomas, for reduction in some tumor size
  • Acromegaly
  • Parkinson's disease, parkinsonism, neuroleptic malignant syndrome
  • Reducing the symptoms of cocaine withdrawal (off-label uses)

    Dosage and administration:

    It is recommended that Parlodel (Bromocriptine Mesylate) be taken with food. Patients should be evaluated frequently during dose escalation to determine the lowest dosage that produces a therapeutic response.


    The most commonly reported signs and symptoms associated with acute Parlodel (Bromocriptine Mesylate) pills overdose are: constipation, nausea, vomiting, diaphoresis, pallor, dizziness, severe hypotension, confusion, malaise, lethargy, delusions, drowsiness, hallucinations, and repetitive yawning. The lethal dose has not been established and the drug has a very wide margin of safety. However, one death occurred in a patient who committed suicide with an unknown quantity of Parlodel and chloroquine.

    Treatment of overdose consists of removal of the drug by emesis (if conscious), gastric lavage, activated charcoal, or saline catharsis. Careful supervision and recording of fluid intake and output is essential. Hypotension should be treated by placing the patient in the Trendelenburg position and administering I.V. fluids. If satisfactory relief of hypotension cannot be achieved by using the above measures to their fullest extent, vasopressors should be considered.

    There have been isolated reports of children who accidentally ingested Parlodel. Vomiting, somnolence and fever were reported as adverse events. Patients recovered either spontaneously within a few hours or after appropriate management.

    Dosage forms and strengths:

  • Parlodel (Bromocriptine Mesylate) 2.5 mg round, off-white, bevelled-edge SnapTabs. Inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, maleic acid, povidone, starch.
  • Parlodel (Bromocriptine Mesylate) 5 mg white capsules. Inactive ingredients: colloidal silicon dioxide, gelatin, lactose, magnesium stearate, red iron oxide, silicon dioxide, sodium lauryl sulfate, starch, maleic acid, titanium dioxide, yellow iron oxide.


    Hypersensitivity to bromocriptine or to any of the excipients of Parlodel capsules or tablets, uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, Parlodel should be withdrawn when pregnancy is diagnosed. In the event that Parlodel is reinstituted to control a rapidly expanding macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing this medication must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When Parlodel is being used to treat acromegaly, prolactinoma, or Parkinson's disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of this medicine is considered to be medically contraindicated.

    The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period, the patient should be observed with caution.


  • Since hyperprolactinemia with amenorrhea/galactorrhea and infertility has been found in patients with pituitary tumors, a complete evaluation of the pituitary is indicated before treatment with Parlodel.
  • If pregnancy occurs during this drug administration, careful observation of these patients is mandatory. Prolactin-secreting adenomas may expand and compression of the optic or other cranial nerves may occur, emergency pituitary surgery becoming necessary.
  • Parlodel has been associated with somnolence, and episodes of sudden sleep onset, particularly in patients with Parkinson's disease.
  • Symptomatic hypotension can occur in patients treated with this medication for any indication.
  • Since, especially during the first days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, particular care should be exercised when driving a vehicle or operating machinery.
  • While hypotension during the start of therapy with Parlodel occurs in some patients, in rare cases serious adverse events, including hypertension, myocardial infarction, seizures, stroke, have been reported in postpartum women treated with Parlodel for the inhibition of lactation.
  • Among patients on this medicines, particularly on long-term and high-dose treatment, pleural and pericardial effusions, as well as pleural and pulmonary fibrosis and constrictive pericarditis, have been reported.
  • In a few patients on Parlodel (Bromocriptine Mesylate) pills, particularly on long-term and high-dose treatment, retroperitoneal fibrosis has been reported.


  • Safety and efficacy of this drug have not been established in patients with renal or hepatic disease.
  • Parlodel pills should be used with caution in patients with a history of psychosis or cardiovascular disease. If acromegalic patients or patients with prolactinoma or Parkinson's disease are being treated with this medication during pregnancy, they should be cautiously observed, particularly during the postpartum period if they have a history of cardiovascular disease.
  • Patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take this medicine.
  • Hyperprolactinemic states: visual field impairment is a known complication of macroprolactinoma.
  • Acromegaly: cold-sensitive digital vasospasm has been observed in some acromegalic patients treated with Parlodel.
  • Parkinson's disease: safety during long-term use for more than 2 years at the doses required for parkinsonism has not been established.

    Adverse reactions, side effects:

    Most frequent adverse reactions of this medicine include: nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre.

    To report suspected side effects of Parlodel (Bromocriptine Mesylate) tablets and tablets contact Novartis pharmaceutical company or your local FDA.

    Drug interactions:

  • The risk of using Parlodel in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of this drug.
  • Parlodel (Bromocriptine) may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of this medication: phenothiazines, haloperidol, metoclopramide, and pimozide.
  • Bromocriptine is a substrate of CYP3A4. Caution should therefore be used when co-administering drugs which are strong inhibitors of this enzyme (such as azole antimycotics, HIV protease inhibitors).
  • The concomitant use of macrolide antibiotics such as erythromycin was shown to increase the plasma levels of bromocriptine (mean AUC and Cmax values increased 3.7-fold and 4.6-fold, respectively).
  • The concomitant treatment of acromegalic patients with bromocriptine and octreotide led to increased plasma levels of bromocriptine (bromocriptine AUC increased about 38%).
  • Concomitant use of Parlodel with other ergot alkaloids is not recommended. Dose adjustment may be necessary in those cases where high doses of bromocriptine are being used (such as Parkinson's disease indication).

    Related medications:

  • Ambien (Zolpidem Tartrate) 10 mg
  • Clomid tablets

    Use in specific populations:


    Administration of 10-30 mg/kg of bromocriptine to 2 strains of rats on days 6 to 15 postcoitum (p.c.) as well as a single dose of 10 mg/kg on day 5 p.c. interfered with nidation.

    No teratological or embryotoxic effects of bromocriptine were produced in any of 6 offspring from 6 monkeys at a dose level of 2 mg/kg.

    There is no suggestion that Parlodel contributed to the type or incidence of birth defects in this group of infants.


    Parlodel should not be used during lactation in postpartum women.

    Pediatric use

    The safety and effectiveness of bromocriptine for the treatment of prolactin-secreting pituitary adenomas have been established in patients age 16 to adult. No data are available for bromocriptine use in pediatric patients under the age of 8 years.

    Geriatric use

    Clinical studies for Parlodel did not include sufficient numbers of subjects aged 65 and over to determine whether the elderly respond differently from younger subjects.

    Information for patients:

    During clinical trials, dizziness, drowsiness, faintness, fainting, and syncope have been reported early in the course of Parlodel therapy. In postmarketing reports, this medication has been associated with somnolence, and episodes of sudden sleep onset, particularly in patients with Parkinson's disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. All patients receiving Parlodel should be cautioned with regard to engaging in activities requiring rapid and precise responses, such as driving an automobile or operating machinery. Patients being treated with this medicine and presenting with somnolence and/or sudden sleep episodes must be advised not to drive or engage in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g., operating machines).

    Patients receiving Parlodel (Bromocriptine Mesylate) tablets or capsules for hyperprolactinemic states associated with macroadenoma or those who have had previous transsphenoidal surgery should be told to report any persistent watery nasal discharge to their physician. Patients receiving this drug for treatment of a macroadenoma should be told that discontinuation of drug may be associated with rapid regrowth of the tumor and recurrence of their original symptoms.

    Patients and their caregivers should be alerted to the possibility that they may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges and other intense urges and the inability to control these urges while taking Parlodel.

    Especially during the first days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, particular care should be exercised when driving a vehicle or operating machinery.

    Where to buy bromocriptine online:

    To purchase Parlodel (Bromocriptine Mesylate) tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

    Here is a list of popular medications containing bromocriptine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
  • Tablets, Film-Coated; Oral; Bromocriptine Mesylate 2.5 mg
  • Novartis
  • Lek
  • Sandoz
  • Parlodel
  • Capsules; Oral; Bromocriptine Mesylate 5 mg, 10 mg
  • Tablets, Film-Coated; Oral; Bromocriptine Mesylate 1.25 mg, 2.5 mg, 5 mg
  • Novartis
  • Aspen
  • Meda
  • Mitra Healthcare
  • Sandoz
  • Validus Pharmaceuticals
  • Pravidel
  • Capsules; Oral; Bromocriptine Mesylate 5 mg, 10 mg
  • Tablets; Oral; Bromocriptine Mesylate 2.5 mg
  • Novartis
  • Proctinal
  • Tablets; Oral; Bromocriptine Mesylate 1.25 mg, 2.5 mg
  • GlaxoSmithKline
  • Sicriptin
  • Tablets; Oral; Bromocriptine Mesylate 1.25 mg, 2.5 mg
  • Serum Institute of India